What question did this study set out to answer?

This research aims to assess the impact of CD34 expression on induction therapy response in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

March 10, 2022Molecular OncologyOpen Access

High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion

View Full Paper

Ask AI

Bookmark

This research aims to assess the impact of CD34 expression on induction therapy response in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Analyzed 200 BCP-ALL patients using flow cytometry for immunophenotyping.
Evaluated the association of CD34 expression with minimal residual disease (MRD) levels and relapse risk.
Identified gene expression profiles related to CD34 positivity.
CD34-positive patients had a significantly higher MRD level of ≥ 0.001 at the end of induction therapy (EOI).
CD34-negative patients exhibited a low risk of relapse, suggesting better prognosis.
Gene expression analysis revealed upregulation of genes involved in cell migration, adhesion, and negative regulation of apoptosis in CD34-positive leukemias.

No takes yet. Share an insight, caveat, or question.

Randomized trial finds high CD34 expression correlates with poor therapy response in BCP-ALL, suggesting a need for targeted interventions.

Modvig et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial finds high CD34 expression correlates with poor therapy response in BCP-ALL, suggesting a need for targeted interventions.